The chemotherapeutic agent oxaliplatin, a platinum-based antineoplastic agent, is generally considered as the first-line chemotherapy for CRC patients.13 Oxaliplatin induces DNA cross-links and excessive production of ROS, which cause cytotoxic effects by promoting apoptosis.14, 15 Given that oxaliplatin treatment induces ROS generation, we hypothesized that G6PD-mediated NADPH homeostasis may have the capacity to protect against oxidative stress, resulting in chemoresistance. Here, G6PD is linked to colorectal carcinoma.